New York State Common Retirement Fund Sells 20,083 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

New York State Common Retirement Fund trimmed its position in Ascendis Pharma A/S (NASDAQ:ASND) by 10.1% in the third quarter, HoldingsChannel reports. The firm owned 179,318 shares of the biotechnology company’s stock after selling 20,083 shares during the quarter. New York State Common Retirement Fund’s holdings in Ascendis Pharma A/S were worth $26,774,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ASND. Avoro Capital Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after acquiring an additional 229,995 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in shares of Ascendis Pharma A/S by 1.1% during the 1st quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock worth $616,050,000 after purchasing an additional 44,580 shares during the period. Capital International Investors raised its stake in shares of Ascendis Pharma A/S by 0.5% during the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock worth $331,261,000 after purchasing an additional 10,044 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after buying an additional 336,976 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in Ascendis Pharma A/S by 5.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock valued at $233,348,000 after buying an additional 93,185 shares during the period.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Bank of America increased their target price on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. JPMorgan Chase & Co. dropped their price target on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. The Goldman Sachs Group raised their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Wells Fargo & Company boosted their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Finally, Jefferies Financial Group boosted their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $195.92.

Ascendis Pharma A/S Trading Up 2.0 %

ASND opened at $125.28 on Monday. The business’s 50-day moving average price is $133.42 and its 200-day moving average price is $133.62. Ascendis Pharma A/S has a 12 month low of $86.54 and a 12 month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. On average, equities analysts forecast that Ascendis Pharma A/S will post -7.24 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.